
General : Dr Falk Pharma Reports Positive Phase 3 Results For NCA In Rare Liver Disease
KUALA LUMPUR, May 7 (Bernama) -- Dr Falk Pharma, a research-based pharmaceutical company specialising in digestive and metabolic medicine, has announced positive topline results from its pivotal phase 3 trial (NUC-5) on norucholic acid (NCA) for the …